Acceleron Pharma 2017 R&D Day

September 19, 2017

Members of the Acceleron leadership team will discuss the R&D strategy, long-term vision for the Company, and its clinical development programs across a range of disease areas, including neuromuscular disease and hematology. External experts, along with Acceleron, will provide insight into the current treatment of myelodysplastic syndromes (MDS), beta-thalassemia, and neuromuscular diseases. The Company will also present its latest preclinical research in a new therapeutic area of interest.

Guest external speakers include:

  • Maria Domenica Cappellini, M.D., Director of the Department of Clinical Sciences, Director of the Unit of Internal Medicine, University of Milan, Italy
  • David Steensma, M.D., Senior Physician, Dana-Farber Cancer Institute, Associate Professor of Medicine, Harvard Medical School
  • Martin Childers, D.O., Ph.D., Professor of Rehabilitation Medicine, Co-Director, MDA Clinic, University of Washington, Co-Director, Institute for Stem Cell and Regenerative Medicine
Register / Log Back in

Additional menu options can be found in the menu bar on the left or at the top.

Acceleron Pharma Inc XLRN
Lead ther­a­peu­tic can­di­date, lus­pa­ter­cept, is cur­rent­ly in Ph 3 studies for the treat­ment of ane­mia in MDS and be­ta-tha­lassemia un­der a glob­al part­n­er­ship with Cel­gene. The Com­pany has an ad­di­tio­n­al 3... [more in­for­ma­tion]

Event Contact

Clayton Robertson
The Trout Group, LLC